Clinical Trials
61 trialsABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL
Institute of Hematology & Blood Diseases Hospital, China
BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation
City of Hope Medical Center
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
QuANTUM-WILD
Daiichi Sankyo
The Efficacy of Allo-HSCT in ND HR-CBF-AML
Ruijin Hospital
FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
Syndax Pharmaceuticals
GRAALL-2024
Assistance Publique - Hôpitaux de Paris
Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia
Beijing 302 Hospital
The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid Leukemia
Ruijin Hospital
Repurposing Itraconazole as an Adjuvant Therapy in Treatment of Patients With Acute Myeloid Leukemia: Is it a Hopeful Avenue for Enhancing Treatment Options?
Mansoura University
CLL1818
Gruppo Italiano Malattie EMatologiche dell'Adulto
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL
Gruppo Italiano Malattie EMatologiche dell'Adulto
LAL2317
Gruppo Italiano Malattie EMatologiche dell'Adulto
ROOT
Taproot Health
Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
University of Nebraska
QuANTUM-First
Daiichi Sankyo
A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)
Novartis
UKALL60+
University College, London
Risk Stratification-directed Therapy for AML With t(8;21) /AML1-ETO+
Nanfang Hospital, Southern Medical University
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
AbbVie
Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT
Chinese PLA General Hospital
Decitabine, Cytarabine, GCSF for Refractory AML/MDS
Brown University
A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
AbbVie
Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations
University of Ulm
HINKL
Technische Universität Dresden
LAUNCH
Nohla Therapeutics, Inc.
Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
University of Washington
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma
Fred Hutchinson Cancer Center
Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients
Peking University
Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay
University of Washington
PTX-II
University of Guadalajara
DCHA as Postremission Therapy for AML With t(8;21)
Chinese PLA General Hospital
Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
Eastern Cooperative Oncology Group
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
St. Jude Children's Research Hospital
Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone
Vanderbilt University Medical Center
An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)
Hoffmann-La Roche
A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT
Swedish Orphan Biovitrum
Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support
Swedish Orphan Biovitrum
Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment
Children's Oncology Group
Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors
St. Jude Children's Research Hospital
Timed-Sequential Induction in CBF-AML
Assistance Publique - Hôpitaux de Paris
Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia
National Cancer Institute (NCI)
Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia
National Cancer Institute (NCI)
Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma
National Cancer Institute (NCI)